Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Linagliptin · Tradjenta

Small molecule · Inhibitor of DPP-4 · developed by Boehringer Ingelheim

Approved FDA, May 2011

1 Registered trials

What is Linagliptin?

Linagliptin is an orally bioavailable small-molecule inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases active incretin hormone concentrations (GLP-1 and GIP), stimulating glucose-dependent insulin secretion and reducing glucagon levels to improve glucose homeostasis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Tradjenta
Drug type: Small molecule
Targets: DPP-4
Mechanism: Inhibitor of DPP-4
Pathways: incretin signaling, glucose homeostasis, insulin secretion
Therapy area: Oncology
Developer: Boehringer Ingelheim
In trials of: BLRX
FDA status: Approved as Tradjenta (May 2, 2011), NDA201280 · FDA label

✅ FDA-approved uses

Type 2 diabetes mellitus

From the indications section of the FDA label (version of Aug 27, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03281369	Phase 1/2	Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or…	Terminated	BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z